ENGLISH
Abbott Header Logo
Logo Image

Torch testing

Get in Touch
Torch background image
Torch background image
Torch background image

Congenital infections

When you are pregnant, your greatest priority is protecting your baby. Congenital infections are caused by several pathogens that can be transmitted from the mother to the baby. These infections cause little to no symptoms in healthy adults; however, they severely affect the unborn fetus or newborn baby. Therefore, screening for these pathogens can help reduce the risk of fetal death and potentially life-threatening adverse effects. 

Abbott offers reliable and accurate TORCH testing solutions that can differentiate and help identify congenital infections early. TORCH is an acronym for a group of infections that can be transmitted from the mother to the baby during pregnancy, during childbirth, or shortly after birth:  Toxoplasma gondii, Rubella, Cytomegalovirus (CMV), Herpes Simplex Virus (HSV), and other infections such as syphilis.1

 For in vitro diagnostic use.

10-30%

of all stillbirths have infectious etiology2

~3%

of live births have congenital anomalies present2

Depending on the pathogen

Up to 50%

of pregnancies with congenital infections may result in loss of a baby or fetal death2

Torch testing: every baby deserves a healthy beginning

Healthcare providers are commonly challenged with unknown or potentially serious cases of prenatal infection.

Serological testing can help quickly confirm infection and substantially help reduce the risk of infection to the mother and a baby.

TOrch container bgd img
TOrch container bgd img

Torch barriers

Reducing the burden of congenital infections can be accomplished by overcoming some basic challenges.

Early detection3

Early screening can play a role in the early identification of TORCH infections which may help reduce the risk of complications and life-threatening adverse effect to the baby.

Infection awareness

Knowing one’s infection status can help increase the probability for receiving early treatment and valuable education on safe practices to reduce the risk of exposure.

Testing guidelines

Many patients fail to be tested due to the absence of clear guidelines. Heightened global awareness among clinicians and the general population can accelerate early detection.

Torch panel value

Harness the power of Abbott's torch panel to streamline testing, elevate performance, and help increase the probability of confidently identifying congenital infections.

Confident results

  • Highly specific assays
  • High sensitivity for the early detection of infection
  • Easy interpretation of results
  • Full automation from primary tube to result minimizes the chance of human error
  • Ready-to- use calibrators and controls reduces the possibility of reconstitution errors

Optimized efficiency

  • Consolidation of TORCH assays on Alinity i and ARCHITECT
  • Streamlines testing – minimizes hands-on time
  • Quick results reduce turn-around times
  • Highly specific assays - avoid re-runs and confirmation testing
  • Wide array of sample types: serum and plasma
Abbott's assays

Toxo IgM | Toxo IgG | Toxo IgG Avidity | Rubella IgM | Rubella IgG 

CMV IgM | CMV IgG | CMV IgG Avidity | HSV-1 IgG | HSV-2 IgG

 

TOrch container bgd img
TOrch container bgd img

Supporting
Publications

Learn more about the performance of Abbott's TORCH assays from peer reviewed journals.

Check back for more resources.

PUBLICATIONDESCRIPTION
IgG Avidity Test to Discriminate between Acute and Chronic Toxoplasmosis
Evaluation of the Abbott's ARCHITECT Avidity assay in detecting latent infection in the presence of persistent IgM.
Comparative evaluation of the ARCHITECT Toxo IgG, IgM and IgG Avidity assays for anti-Toxoplasma antibodies detection in pregnant women sera
Study highlights the value of the Abbott's ARCHITECT for the analysis of all clinical situations concerning Toxoplasma gondii serology.
Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus
An Italian study published in the Journal of Clinical Virology highlights the performance of the ARCHITECT analyzer in comparison with other commercial methods.
Evaluation of the New ARCHITECT Cytomegalovirus Immunoglobulin M (IgM), IgG, and IgG Avidity Assays
A team of researchers from Belgium evaluates the ARCHITECT CMV immunoassays with several well-established comparator assays.
Evaluation of the Abbott ARCHITECT cytomegalovirus IgG/IgM, rubella IgG/IgM, and syphilis treponemal enzyme immunoassays in a mother and child health center population
Researchers from Montreal, Quebec, Canada assessed chemiluminescent microparticle immunoassays in mixed pediatric and women of childbearing age population.
Comparison of the two fully automated anti-HCMV assays: Abbott ARCHITECT CMV IgG assay and Biotest anti-HCMV recombinant IgG ELISA
A study published in Transfusion Medicine assessed the performance of CMIA and ELISA immunoassays under routine conditions in a transfusion laboratory.
Kinetics of CMV seroconversion in a Swiss pregnant population
Evaluation of CMV serology to determine the utility and validity of recommended CMV serologic diagnostic algorithms.

Explore

Infectious Disease Assays 

Our extensive assay menu helps physicians make timely, informed decisions throughout the continuum of care.

Explore infectious disease

Infectious Disease Webinars

Learn more about our impact on infectious disease by viewing our webinars.

Explore the webinars

Alinity Family

Discover how Alinity uses technology to redefine and improve operational productivity and confidence in your laboratory.

Get to know alinity
 References

  1. TORCH. AACC: Lab Tests Online. https://labtestsonline.org/tests/torch. Updated September 22, 2020. Accessed March 3, 2021.

  2. Megli, Christina J, and Carolyn B Coyne. “Infections at the Maternal-Fetal Interface: An Overview of Pathogenesis and Defence.” Nature Reviews. Microbiology, Nature Publishing Group UK, 25 Aug. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386341/. 

  3. Wurcel, Victoria, et al. “The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems.” Public Health Genomics, vol. 22, no. 1-2, 2019, pp. 8–15., https://doi.org/10.1159/000501832. 

Logo Image

©2024 Abbott. All rights reserved.

All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. Any person depicted in such photos may be a model. Please read the Legal Notice for further details.

All ARCHITECT analyzers, Alinity hq, CELL-DYN Ruby and CELL-DYN Emerald 22 AL instruments are Class I laser products. ACCELERATOR APS and ACCELERATOR a3600 are Class II laser products.

The Alinity, ARCHITECT and CELL-DYN systems are intended for performing in vitro diagnostic assays on samples of human origin. Read the instructions in the system manuals and labeling and/or reagent instructions carefully.

This website contains general information about our products sold worldwide. Product availability varies by country. For product availability in your country, please contact your local representative from Abbott. Certain products described or certain features of some products described on this global page might not be commercially available in your country. Content is intended for healthcare professionals only.

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

NO